Welcome to our podcast, designed specifically for biotech executives passionate about drug development. Join us as we explore a wide range of engaging topics, from cutting-edge advancements in translational sciences to the latest regulatory updates. Let’s navigate this dynamic landscape together and stay ahead of the curve!
www.drugdevelop.com (https://www.drugdevelop.com?utm_medium=podcast)
State Of The Art in SLE: For Biotech CMOs and CSOs
This podcast summarizes the therapeutic landscape and the underlying molecular understanding of the causal pathways in lupus.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe (https://www.drugdevelop.com/subscribe?utm_medium=podcast&utm_campaign=CTA_2)
14 Jul 2025
mAbs vs CAR-T: A Head-to-Head Comparison for CMOs and CSOs
CAR-T Illustration. Courtesy New Scientist
A recent head-to-head study assessed the comparative effectiveness of different B-cell depletion strategies in patients with autoimmune diseases, specifically comparing protein-based therapies like obinutuzumab (OBI), blinatumomab (BLI), and rituximab (RTX) with cell-based CD19 chimeric antigen receptor (CAR) T-cell therapy. Researchers analyzed lymph node biopsies to assess the extent of B-cell depletion and changes in follicular architecture. They documented that CAR-T was most effective in depleting B cells and disrupting follicular architecture, and concluded that these data indicate potential superiority of CAR-T cell therapies.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe (https://www.drugdevelop.com/subscribe?utm_medium=podcast&utm_campaign=CTA_2)
7 Jul 2025
Type 5 Diabetes: For CMOs and CSOs
Chief Medical Officers and Chief Science Officers explore Type 5 Diabetes and its implications for drug development in this episode.
6 Jul 2025
B-cell depletion for autoimmune diseases: For Biotech CMOs and CSOs
Industry experts explore how novel B-cell depletion strategies aim to revolutionize autoimmune disease treatment by potentially resetting the immune system, in this episode.
3 Jul 2025
Interleukin-6 and Cardioimmunology: For CMOs and CSOs
Industry experts explore interleukin-6 signaling's role in cardiovascular diseases, examining tocilizumab and ziltivekimab's therapeutic potential while considering treatment complexities and the need for personalized approaches.
29 Jun 2025
CAR T-Cell Therapy trials in Lupus just got a bit easier: For Biotech CMOs and CSOs
This episode discusses CAR T-cell therapy trials in Lupus and its implications for Biotech CMOs and CSOs, offering insights into streamlining drug development; this is not an interview.
29 Jun 2025
Fast Approvals with FDA's Voucher Programs: For Biotech CMOs and CSOs
Industry experts examine the FDA's voucher programs and accelerated approval pathways for biotech companies, offering insights for Chief Medical Officers and Chief Science Officers in this interview.
24 Jun 2025
Digital Twins For Biotech CMOs and CSOs
This episode explores digital twins for biotech CMOs and CSOs, offering insights into their application within drug development.
21 Jun 2025
Digital Twins for CSOs and CMOs
This episode explores how Chief Science Officers and Chief Medical Officers utilize digital twins in drug development.
8 Jun 2025
FDAs Recent Roundtable on Cell and Gene Therapies
This episode summarizes the FDA's June 6, 2025, roundtable discussion regarding cell and gene therapies.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Podcast Authority Score: 22 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
45
Social presence
0
YouTube
0
Engagement
0
Host of Drug Development Executive?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
